$RGEN

REPLIGEN CORP

Repligen develops and commercializes bioprocessing technologies and systems for manufacturers of biological drugs. Its customers include global biopharmaceutical companies, contract development and manufacturing organizations, other life science companies, diagnostics companies and laboratory researchers. Repligen operates as one bioprocessing business, supplying products for upstream and downstream manufacturing processes. It is headquartered in Waltham, Massachusetts. Its four main product franchises are Filtration, including fluid management; Chromatography; Process Analytics, branded PATsmart; and Proteins. Products include filtration systems and consumables, chromatography columns and systems, process-monitoring instruments, affinity ligands and resins, and cell culture growth factors. Repligen also offers custom ligand and resin development services. It makes money primarily from sales of consumable and single-use products, as well as hardware and equipment.

AlphAI earnings readQ3 FY2026 · OCT 27Repligen Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Financial GuidanceVerdict: solid

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

No enriched coverage for $RGEN in the last 7 days.

No SEC Form 4 filings for $RGEN in the last 30 days.

See all $RGEN insider activity →
High

Repligen Issues $1 Billion of 0.25% Convertible Notes Due 2031

Repligen issued $1.0 billion of 0.25% convertible senior notes due 2031, refinancing part of existing debt and raising additional cash. The offering included $541.4 million exchanged for 2028 notes and $458.6 million sold for cash, with $143.2 million of 2028 notes remaining.

REPLIGEN CORP (RGEN): Entry into a Material Definitive Agreement

REPLIGEN CORP (RGEN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On November 6, 2026, in connection with the consummation of previously announced private exchange and subscription transactions, Repligen Corporation (the “Company”) issued $1.0 billion aggregate principal amount of its 0.25%

RGEN Q3 deep dive: margin headwinds and BioLife integration shape improved full-year outlook

Repligen reported Q3 revenue of $209.3M, beating estimates, with adjusted EPS of $0.53 and adjusted EBITDA of $43.84M. The company raised full-year revenue guidance to $848M and adjusted EPS to $2.07. Growth was driven by proteins and chromatography segments, while filtration revenue declined. The BioLife acquisition is expected to drive future growth and margin expansion.

RGEN sentiment & insider activity

Recent RGEN coverage spans corporate actions, earnings and financial news.

What's driving RGEN

AlphAI scores every news story that mentions RGEN with an AI model for sentiment and relevance, and aggregates insider trades from REPLIGEN CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $RGEN

Score
$RGENMedOffering· $1B · closed

REPLIGEN CORP (RGEN): Entry into a Material Definitive Agreement

REPLIGEN CORP (RGEN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On November 6, 2026, in connection with the consummation of previously announced private exchange and subscription transactions, Repligen Corporation (the “Company”) issued $1.0 billion aggregate principal amount of its 0.25%

RGEN Q3 deep dive: margin headwinds and BioLife integration shape improved full-year outlook

Repligen reported Q3 revenue of $209.3M, beating estimates, with adjusted EPS of $0.53 and adjusted EBITDA of $43.84M. The company raised full-year revenue guidance to $848M and adjusted EPS to $2.07. Growth was driven by proteins and chromatography segments, while filtration revenue declined. The BioLife acquisition is expected to drive future growth and margin expansion.

$RGENHighOffering· 0.25% · proposed

REPLIGEN CORP (RGEN): Unregistered Sales of Equity Securities

REPLIGEN CORP (RGEN) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Exhibit 99.1 October 29, 2026 Repligen Corporation 41 Seyon Street, Bldg. 1, Suite 100 Waltham, MA 02453 Attention: Chief Financial Officer Re: Exchange and/or Subscription for Repligen Corporation 0.25% Convertible Senior Notes due 2031 Ladies and Gentlemen: Repligen Corporation

About $459 million in cash is expected as Repligen exchanges about $457 million in older debt.

Repligen (RGEN) announced debt exchange and subscription agreements, expecting $459M in cash to replace $457M in older debt. The company aims to extend debt duration, reduce interest expense, and enhance financial flexibility. The reduced interest expense is expected to be nominally accretive to adjusted EPS in 2026. Repligen also plans to repurchase common stock, which could impact its market price.

$RGENHighAI 8/10Earnings

Repligen Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance

REPLIGEN CORP (RGEN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 Repligen Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance • Third quarter revenue of $209 million, a year-over-year increase of 11% as r

Related tickers